Exhibit 99.1

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

Overview

On October 31, 2019, pursuant to the previously disclosed Securities Purchase Agreement, dated as of October 10, 2019, by and between MEDNAX Services, Inc., a Florida corporation (“MEDNAX Services”), and wholly-owned subsidiary MEDNAX, Inc., a Florida corporation (the “Company”), and FH MD Buyer, Inc., a Delaware corporation (“Buyer”) and affiliate of Frazier Healthcare Partners, the Company completed the divestiture of MedData Holding Co., a Delaware corporation (“MedData Holding”), and MedDirect Holding Co., a Delaware corporation (“MedDirect Holding” and together with MedData Holdings, the “Purchased Companies”). The Purchased Companies constitute the Company’s management services service line, which operates as MedData. The purchase consideration was comprised of $250 million in cash paid at closing, subject to certain net working capital assumptions, as well as economic consideration in an indirect holding company of Buyer, the value of which is contingent on both short and long-term performance of MedData. The maximum amount payable in respect of such economic consideration is $50 million. The fair value of this contingent consideration is not estimable at this time as the valuation of such consideration is currently in process.

The divestiture of MedData is considered a significant disposition for the Company. As a result, the Company prepared the accompanying unaudited pro forma condensed consolidated financial information in accordance with Article 11 of Regulation S-X.

The Company presented its operations for MedData as discontinued operations in its condensed consolidated financial statements included in the Company’s Form 10-Q for the three and nine months ended September 30, 2019. The accompanying unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2019 and for the years ended December 31, 2018, 2017, and 2016 give effect to the divestiture of MedData as if it occurred on January 1, 2016. The accompanying unaudited pro forma condensed consolidated balance sheet gives effect to the divestiture of MedData as if it occurred on September 30, 2019, the end of the most recent period for which a balance sheet is required.

The accompanying unaudited pro forma condensed consolidated financial information should be read in conjunction with (i) the audited consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and (ii) the unaudited condensed consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” included in the Company’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2019.

The accompanying unaudited pro forma condensed consolidated financial information is presented based on assumptions, adjustments, and currently available information described in the accompanying notes and is intended for informational purposes only. The unaudited pro forma condensed consolidated financial information is not necessarily indicative of what the Company’s results of operations or financial condition would have been had the divestiture of MedData been completed on the dates assumed. In addition, it is not necessarily indicative of the Company’s future results of operations or financial condition.

MEDNAX, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

AS OF SEPTEMBER 30, 2019

(in thousands)

		As Reported				Pro Forma Adjustments				Pro Forma
ASSETS
Current assets:
Cash and cash equivalents		$	28,890				25,200	(a)		$	54,090
Short-term investments			78,371				—				78,371
Accounts receivable, net			494,699				—				494,699
Prepaid expenses			20,937				—				20,937
Other current assets			19,939				—				19,939
Assets held for sale			322,465				(322,465	)(b)			—
Total current assets			965,301				(297,265	)			668,036
Property and equipment, net			93,731				—				93,731
Goodwill			2,634,874				—				2,634,874
Intangible assets, net			279,605				—				279,605
Operating lease right-of-use assets			84,279				—				84,279
Other assets			232,871				—				232,871
Total assets		$	4,290,661				(297,265	)		$	3,993,396
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses		$	441,972				—			$	441,972
Current portion of lease liabilities			23,611				—				23,611
Income taxes payable			4,763				—				4,763
Liabilities held for sale			30,444				(30,444	)(b)			—
Total current liabilities			500,790				(30,444	)			470,346
Line of credit			209,800				(209,800	)(a)			—
Long-term debt and finance lease liabilities, net			1,729,377				—				1,729,377
Long-term operating lease liabilities			65,287				—				65,287
Long-term professional liabilities			222,933				—				222,933
Deferred income taxes			61,207				—				61,207
Other liabilities			21,907				—				21,907
Total liabilities			2,811,301				(240,244	)			2,571,057
Commitments and contingencies
Total equity			1,479,360				(57,021	)(c)			1,422,339
Total liabilities and equity		$	4,290,661				(297,265	)		$	3,993,396

See notes to unaudited Pro Forma Condensed Consolidated Financial Statements.

MEDNAX, INC.

UNAUDTED PRO FORMA CONSDENSED CONSOLIDATED STATEMENT OF OPERATIONS

Nine Months Ended September 30, 2019

(in thousands, except per share data)

		As Reported				Pro Forma Adjustments				Pro Forma
Net revenue		$	2,608,167				—			$	2,608,167
Operating expenses:
Practice salaries and benefits			1,860,810				—				1,860,810
Practice supplies and other operating expenses			80,757				—				80,757
General and administrative expenses			307,717				—				307,717
Depreciation and amortization			59,450				—				59,450
Transformational and restructuring related expenses			51,018				—				51,018
Goodwill impairment			1,449,215				—				1,449,215
Total operating expenses			3,808,967				—				3,808,967
(Loss) income from operations			(1,200,800	)			—				(1,200,800	)
Investment and other income			4,242				—				4,242
Interest expense			(91,704	)			5,680	(d)			(86,024	)
Equity in earnings of unconsolidated affiliates			5,475				—				5,475
Total non-operating expenses			(81,987	)			5,680				(76,307	)
(Loss) income from continuing operations before income taxes			(1,282,787	)			5,680				(1,277,107	)
Income tax benefit (provision)			99,710				(1,545	)(d)			98,165
(Loss) income from continuing operations			(1,183,077	)			4,135				(1,178,942	)
Income (loss) from discontinued operations, net of tax			(323,956	)			323,956	(e)			—
Net (loss) income		$	(1,507,033	)			328,091			$	(1,178,942	)
Per common and common equivalent share data:
(Loss) income from continuing operations:
Basic		$	(14.11	)		$	0.05			$	(14.06	)
Diluted		$	(14.11	)		$	0.05			$	(14.06	)
Income (loss) from discontinued operations:
Basic		$	3.86	)		$	3.86			$	—
Diluted		$	(3.86	)		$	3.86			$	—
Net (loss) income:
Basic		$	(17.97	)		$	3.91			$	(14.06	)
Diluted		$	(17.97	)		$	3.91			$	(14.06	)
Weighted average common shares:
Basic			83,846								83,846
Diluted			83,846								83,846

MEDNAX, INC.

UNAUDTED PRO FORMA CONSDENSED CONSOLIDATED STATEMENT OF OPERATIONS

Year Ended December 31, 2018

(in thousands, except per share data)

		As Reported				Pro Forma Adjustments (f)				Pro Forma
Net revenue		$	3,647,123			$	(192,313	)		$	3,454,810
Operating expenses:
Practice salaries and benefits			2,535,588				(109,212	)			2,426,376
Practice supplies and other operating expenses			122,028				(13,177	)			108,851
General and administrative expenses			432,378				(28,444	)			403,934
Depreciation and amortization			111,281				(27,449	)			83,832
Total operating expenses			3,201,275				(178,282	)			3,022,993
Income from operations			445,848				(14,031	)			431,817
Investment and other income			4,935				276				5,211
Interest expense			(88,769	)			7,876	(d)			(80,893	)
Equity in earnings of unconsolidated affiliates			6,825				—				6,825
Total non-operating expenses			(77,009	)			8,152				(68,857	)
Income before income taxes			368,839				(5,879	)			362,960
Income tax provision			(100,210	)			1,609	(g)(d)			(98,601	)
Net income		$	268,629			$	(4,270	)		$	264,359
Per common and common equivalent share data:
Net income:
Basic			2.95			$	(0.05	)		$	2.90
Diluted			2.93			$	(0.04	)		$	2.89
Weighted average common shares:
Basic			91,104								91,104
Diluted			91,606								91,606

MEDNAX, INC.

UNAUDTED PRO FORMA CONSDENSED CONSOLIDATED STATEMENT OF OPERATIONS

Year Ended December 31, 2017

(in thousands, except per share data)

		As Reported				Pro Forma Adjustments (f)				Pro Forma
Net revenue		$	3,458,312			$	(204,921	)		$	3,253,391
Operating expenses:
Practice salaries and benefits			2,337,734				(110,399	)			2,227,335
Practice supplies and other operating expenses			120,518				(14,074	)			106,444
General and administrative expenses			417,105				(31,241	)			385,864
Depreciation and amortization			102,879				(24,023	)			78,856
Total operating expenses			2,978,236				(179,737	)			2,798,499
Income from operations			480,076				(25,184	)			454,892
Investment and other income			3,953				432				4,385
Interest expense			(74,559	)			3				(74,556	)
Equity in earnings of unconsolidated affiliates			952				—				952
Total non-operating expenses			(69,654	)			435				(69,219	)
Income before income taxes			410,422				(24,749	)			385,673
Income tax provision			(90,050	)			9,819	(g)			(80,231	)
Net income		$	320,372			$	(14,930	)		$	305,442
Per common and common equivalent share data:
Net income:
Basic			3.47			$	(0.16	)		$	3.31
Diluted			3.45			$	(0.16	)		$	3.29
Weighted average common shares:
Basic			92,431								92,431
Diluted			92,958								92,958

MEDNAX, INC.

UNAUDTED PRO FORMA CONSDENSED CONSOLIDATED STATEMENT OF OPERATIONS

Year Ended December 31, 2016

(in thousands, except per share data)

		As Reported				Pro Forma Adjustments (f)				Pro Forma
Net revenue		$	3,183,159			$	(141,349	)		$	3,041,810
Operating expenses:
Practice salaries and benefits			2,031,220				(73,579	)			1,957,641
Practice supplies and other operating expenses			118,416				(10,606	)			107,810
General and administrative expenses			372,572				(25,004	)			347,568
Depreciation and amortization			89,264				(15,083	)			74,181
Total operating expenses			2,611,472				(124,272	)			2,487,200
Income from operations			571,687				(17,077	)			554,610
Investment and other income			2,019				258				2,277
Interest expense			(63,092	)			41				(63,051	)
Equity in earnings of unconsolidated affiliates			3,185				—				3,185
Total non-operating expenses			(57,888	)			299				(57,589	)
Income before income taxes			513,799				(16,778	)			497,021
Income tax provision			(189,203	)			6,601	(g)			(182,602	)
Net income			324,596				(10,177	)			314,419
Net loss attributable to noncontrolling interests			318				—				318
Net income attributable to MEDNAX, Inc.		$	324,914			$	(10,177	)		$	314,737
Per common and common equivalent share data:
Net income attributable to MEDNAX, Inc.:
Basic		$	3.52			$	(0.11	)		$	3.41
Diluted		$	3.49			$	(0.11	)		$	3.38
Weighted average common shares:
Basic			92,422								92,422
Diluted			93,109								93,109

MEDNAX, INC.

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(a) Adjustment reflects the assets and liabilities of the MedData business, which were previously classified as held for sale.

(b) Adjustment reflects the use of cash proceeds from the sale of the MedData business, net of transaction expenses, to repay debt, to the extent debt was outstanding, with the remaining amount as excess cash. The Company did not include a pro forma asset for the contingent consideration payable to the Company as the fair value of such contingent consideration was not able to be estimated on the date of sale as the valuation of such contingent consideration was not yet complete.

(c) Adjustment reflects the estimated loss on the sale of the MedData business. Any change to the estimated loss on sale will be recorded upon completion of the valuation of the contingent consideration referred to in (b).

(d) Adjustment reflects the estimated decrease in interest expense from the use of net cash proceeds from the sale of the MedData business to repay debt and the related income tax impacts from such decrease in interest expense.

(e) Adjustment reflects the historical loss from discontinued operations, net of tax, associated with the MedData business.

(f) Adjustment reflects the discontinued operations of the MedData business, except as otherwise noted.

(g) Adjustment reflects the tax effects of the MedData business divestiture to achieve the pro forma tax for the continuing operations of MEDNAX, Inc.